AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications

An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.